2018-19 Section 7-Neoplastic and Inflammatory Diseases of the Head and Neck eBook

A.M.M. Eggermont, R. Dummer / European Journal of Cancer 86 (2017) 101 e 105

[26] Eggermont AM, Suciu S, Rutkowski P, et al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer 2016;55:111 e 21 . [27] Ives NJ, Suciu S, Eggermont AMM, et al. Adjuvant interferon- a for the treatment of high-risk melanoma: an individual patient data meta-analysis. Eur J Cancer 2017;82:171 e 83 . [28] Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003;29:241 e 52 . [29] Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a system- atic review and meta-analysis. J Natl Cancer Inst 2010;102: 493 e 501 . [30] Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline e update 2016. Eur J Cancer 2016;63:201 e 17 .

[31] Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 2016;17(6):757 e 67 . [32] Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in mela- noma. N Engl J Med 2017;376(23):2211 e 22 . [33] Rozeman EA, Fanchi L, van Akkooi ACJ, et al. (Neo-)adjuvant ipilimumab 1 nivolumab (IPI1NIVO) in palpable stage 3 mela- noma e updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses. Ann Oncol 2017; 28(Suppl 5):1221 . [34] Menzies AM, Gonzalez M, Guminski A, et al. Phase 2 study of neoadjuvant dabrafenib þ trametinib (D1T) for resectable stage IIIB/C BRAF V600 mutant melanoma. Ann Oncol 2017;28(Suppl 5):1221 . [35] Long GV, Atkinson V, Cebon JS, et al. Standard-dose pem- brolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open- label, phase 1b trial. Lancet Oncol 2017 Sep;18(9):1202 e 10 .

62